593 related articles for article (PubMed ID: 15721372)
41. Construction of nanoscale multicompartment liposomes for combinatory drug delivery.
Al-Jamal WT; Kostarelos K
Int J Pharm; 2007 Mar; 331(2):182-5. PubMed ID: 17223294
[TBL] [Abstract][Full Text] [Related]
42. Effect of preparation technique on the properties of liposomes encapsulating ketoprofen-cyclodextrin complexes aimed for transdermal delivery.
Maestrelli F; González-Rodríguez ML; Rabasco AM; Mura P
Int J Pharm; 2006 Apr; 312(1-2):53-60. PubMed ID: 16469460
[TBL] [Abstract][Full Text] [Related]
43. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients.
Mayer LD; Tai LC; Bally MB; Mitilenes GN; Ginsberg RS; Cullis PR
Biochim Biophys Acta; 1990 Jun; 1025(2):143-51. PubMed ID: 2364073
[TBL] [Abstract][Full Text] [Related]
44. Using disaccharides to enhance in vitro and in vivo transgene expression mediated by a lipid-based gene delivery system.
Tseng WC; Tang CH; Fang TY; Su LY
J Gene Med; 2007 Aug; 9(8):659-67. PubMed ID: 17611953
[TBL] [Abstract][Full Text] [Related]
45. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid.
Semple SC; Harasym TO; Clow KA; Ansell SM; Klimuk SK; Hope MJ
J Pharmacol Exp Ther; 2005 Mar; 312(3):1020-6. PubMed ID: 15525796
[TBL] [Abstract][Full Text] [Related]
46. Development of targeted delivery systems for nucleic acid drugs.
Mahato RI; Takakura Y; Hashida M
J Drug Target; 1997; 4(6):337-57. PubMed ID: 9239575
[TBL] [Abstract][Full Text] [Related]
47. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
Wu J; Lu Y; Lee A; Pan X; Yang X; Zhao X; Lee RJ
J Pharm Pharm Sci; 2007; 10(3):350-7. PubMed ID: 17727798
[TBL] [Abstract][Full Text] [Related]
48. Advances in lipid nanodispersions for parenteral drug delivery and targeting.
Constantinides PP; Chaubal MV; Shorr R
Adv Drug Deliv Rev; 2008 Mar; 60(6):757-67. PubMed ID: 18096269
[TBL] [Abstract][Full Text] [Related]
49. Determination of size distribution and encapsulation efficiency of liposome-encapsulated hemoglobin blood substitutes using asymmetric flow field-flow fractionation coupled with multi-angle static light scattering.
Arifin DR; Palmer AF
Biotechnol Prog; 2003; 19(6):1798-811. PubMed ID: 14656159
[TBL] [Abstract][Full Text] [Related]
50. Liposomal drug delivery systems: from concept to clinical applications.
Allen TM; Cullis PR
Adv Drug Deliv Rev; 2013 Jan; 65(1):36-48. PubMed ID: 23036225
[TBL] [Abstract][Full Text] [Related]
51. Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients.
Fenske DB; Wong KF; Maurer E; Maurer N; Leenhouts JM; Boman N; Amankwa L; Cullis PR
Biochim Biophys Acta; 1998 Nov; 1414(1-2):188-204. PubMed ID: 9804953
[TBL] [Abstract][Full Text] [Related]
52. Liposomal delivery of hydrophobic weak acids: enhancement of drug retention using a high intraliposomal pH.
Joguparthi V; Anderson BD
J Pharm Sci; 2008 Jan; 97(1):433-54. PubMed ID: 17918731
[TBL] [Abstract][Full Text] [Related]
53. Glucuronate-modified, long-circulating liposomes for the delivery of anticancer agents.
Oku N; Namba Y
Methods Enzymol; 2005; 391():145-62. PubMed ID: 15721379
[TBL] [Abstract][Full Text] [Related]
54. Physicochemical optimisation of plasmid delivery by cationic lipids.
Tranchant I; Thompson B; Nicolazzi C; Mignet N; Scherman D
J Gene Med; 2004 Feb; 6 Suppl 1():S24-35. PubMed ID: 14978748
[TBL] [Abstract][Full Text] [Related]
55. Delivery of antiviral agents in liposomes.
Düzgüneş N; Simões S; Slepushkin V; Pretzer E; Flasher D; Salem II; Steffan G; Konopka K; Pedroso de Lima MC
Methods Enzymol; 2005; 391():351-73. PubMed ID: 15721391
[TBL] [Abstract][Full Text] [Related]
56. The use of pH-triggered leaky heterogeneities on rigid lipid bilayers to improve intracellular trafficking and therapeutic potential of targeted liposomal immunochemotherapy.
Karve S; Alaouie A; Zhou Y; Rotolo J; Sofou S
Biomaterials; 2009 Oct; 30(30):6055-64. PubMed ID: 19665223
[TBL] [Abstract][Full Text] [Related]
57. Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery.
Lasic DD; Ceh B; Stuart MC; Guo L; Frederik PM; Barenholz Y
Biochim Biophys Acta; 1995 Nov; 1239(2):145-56. PubMed ID: 7488619
[TBL] [Abstract][Full Text] [Related]
58. Factors influencing uptake and retention of amino-containing drugs in large unilamellar vesicles exhibiting transmembrane pH gradients.
Maurer-Spurej E; Wong KF; Maurer N; Fenske DB; Cullis PR
Biochim Biophys Acta; 1999 Jan; 1416(1-2):1-10. PubMed ID: 9889298
[TBL] [Abstract][Full Text] [Related]
59. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
[TBL] [Abstract][Full Text] [Related]
60. pH-sensitive liposomes--principle and application in cancer therapy.
Karanth H; Murthy RS
J Pharm Pharmacol; 2007 Apr; 59(4):469-83. PubMed ID: 17430630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
